Medtronic

Medtronic’s new Transcatheter pulmonary valve study, approved by the FDA, represents the first time this new draft guidance has been employed. The result should be a better product, earlier to market, if the klegislation is doing its job.

Medtronic, Inc. has announced that the U.S. FDA has approved the 34mm and 38mm lengths of the Resolute Integrity drug-eluting stent in diameters of 3.0mm, 3.5mm and 4.0mm. The longer lengths include an indication for patients with diabetes in whom longer lesions are common.

Medtronic, the global leader in the $2 billion per year fast growing Aortic Endografts Market is rumoured to be about to increase its stake by acquiring new paradigm shifting technology that addresses the under-served needs of patients thoraco-abdominal aneurysms

Medtronic has gained FDA approval and will commence U.S. launch of its Advisa DR MRI™ SureScan® pacing system. The system is Medtronic’s second-generation MR-Conditional pacemaker and is the first to combine the most advanced pacing technology with proven MRI access.

We’re always on the look-out for technologies that nudge the state of play forward. Medtronic’s next-generation Evera® ICDs offer patients proven treatment performance, increased longevity, improved comfort and are now CE marked.

Medtronic is trumpeting the European introduction of the first and only implantable neurostimulation systems indicated for use in the treatment of chronic back and/or leg pain that are designed for full-body MRI scans under specific conditions.

Medtronic, Inc. has announced the start of PROMISE, the first ever, large-scale study comparing the effectiveness of its neurostimulation therapy plus optimal medical management to optimal medical management alone in failed back surgery patients.

Medtronic, Inc. has announced the CE mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities, specifically the superficial femoral arteries and proximal popliteal arteries.

When a company enters into a study as big as this one, it must be pretty confident of a favourable outcome. In the case of Medtronic’s New CRT-P study the company will win big if it can show patient benefit from treating earlier stage heart failure.

GI Dynamics has announced that it has entered into separate research collaborations with GlaxoSmithKline and Medtronic in an effort to understanding how EndoBarrier® works in relation to diabetes.

A therapy as potentially huge as renal denervation is bound to be tied up in claim and counterclaim, and downright confusion about who owns what. A new article tries to unpick it all.

Published data demonstrate the Symplicity™ renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months

Medtronic, Inc. has gained CE Mark approval for its innovative Sentrino® Continuous Glucose Management System, the first minimally invasive continuous glucose monitoring system specifically designed for use in hospital critical care units.

Medtronic’s Heart Pacing and Spine business areas seem to be the only real lowlights on the company’s reported quarterly financials and there are some areas where growth is definitely outstripping the market, so they must be doing something right.

So the two biggest players in the TAVI game are slugging it out over intellectual property in what promises to be a do or die moment for Medtronic’s CoreValve implant.

Medtronic’s Valiant Thoracic Stent Graft has become the second device to be FDA approved for use in all descending thoracic aortic aneurysms without dissections.